Related Experiment Video

Updated: Jul 18, 2026

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
05:08

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

Beta-adrenergic pathways in human heart failure

Carmen C Sucharov1

  • 1Division of Cardiology, University of Colorado Health Sciences Center, 4200 E Ninth Ave, Denver, CO 80262, USA. kika.sucharov@uchsc.edu

Expert Review of Cardiovascular Therapy
|December 26, 2006
PubMed

Insights

Beta-adrenergic receptor activation impacts heart failure. This review explores downstream signaling pathways, including PDE3, phospholamban phosphorylation, and CaMKII activation, as potential new targets for heart failure treatment.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Pharmacology

Background:

  • Beta-adrenergic receptor (BAR) activation is crucial in human heart failure (HF) progression.
  • Beta-blocker therapy has improved HF outcomes but an unmet need for novel therapeutic targets persists.
  • Understanding downstream signaling pathways of BAR stimulation is key for developing new HF treatments.

Purpose of the Study:

  • To review the significance of downstream signaling pathways activated by beta-adrenergic stimulation in the pathophysiology of heart failure.
  • To highlight potential therapeutic targets for heart failure based on these signaling pathways.

Main Methods:

  • Literature review focusing on studies analyzing downstream signaling pathways of beta-adrenergic stimulation in heart failure.
  • Detailed discussion of the roles of phosphodiesterase 3 (PDE3), phospholamban phosphorylation, and calcium/calmodulin-dependent protein kinase II (CaMKII) activation.

Main Results:

  • Beta-adrenergic stimulation activates specific downstream pathways implicated in heart failure.
  • PDE3, phospholamban phosphorylation, and CaMKII activation are identified as critical mediators in the context of beta-adrenergic signaling in HF.
  • These pathways represent promising targets for future heart failure therapeutics.

Conclusions:

  • Targeting specific downstream effectors of beta-adrenergic receptor activation, such as PDE3, phospholamban phosphorylation, and CaMKII, offers a promising avenue for novel heart failure therapies.
  • Further research into these pathways could lead to improved treatment strategies for patients with heart failure.

More Related Videos

Rodent Working Heart Model for the Study of Myocardial Performance and Oxygen Consumption12:43

Rodent Working Heart Model for the Study of Myocardial Performance and Oxygen Consumption

Published on: August 16, 2016

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Adrenergic Receptors (Adrenoceptors): Classification01:27

Adrenergic Receptors (Adrenoceptors): Classification

Adrenergic receptors, or adrenoceptors, respond to the autonomic neurotransmitter noradrenaline and other endogenous catecholamine agonists. They are classified into two main families, α and β, based on their pharmacological response and are further subdivided depending on their location, elicited response, and affinity to specific agonists or antagonists.
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors, which are found on postsynaptic...
Sympathetic Signaling01:31

Sympathetic Signaling

Sympathetic signaling, a vital part of the autonomic nervous system, plays a crucial role in mobilizing the body's resources in response to stress or emergencies. It involves the transmission of nerve impulses from sympathetic preganglionic fibers to postganglionic fibers. This results in the release of specific neurotransmitters and activation of adrenergic receptors.
Sympathetic preganglionic fibers release the neurotransmitter acetylcholine (ACh) onto the ganglionic neurons in the...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...